$CELU
Celularity Inc

2021 Q4 Form 10-Q Financial Statement

#000156459021056724 Filed on November 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021 Q2
Revenue $4.856M $10.62M $5.857M
YoY Change 216.6%
Cost Of Revenue $4.660M $2.311M $2.682M
YoY Change
Gross Profit $196.0K $8.311M $3.175M
YoY Change 257.92%
Gross Profit Margin 4.04% 78.24% 54.21%
Selling, General & Admin $13.21M $21.64M $36.49M
YoY Change 159.93%
% of Gross Profit 6738.78% 260.43% 1149.26%
Research & Development $24.69M $23.77M $39.90M
YoY Change 111.87%
% of Gross Profit 12595.41% 285.95% 1256.72%
Depreciation & Amortization $2.606M $1.792M $1.087M
YoY Change 18.52%
% of Gross Profit 1329.59% 21.56% 34.24%
Operating Expenses $15.15M $45.41M $108.2M
YoY Change 325.26% 132.34% 51852.65%
Operating Profit -$14.95M $10.90M -$105.0M
YoY Change -326.76%
Interest Expense -$751.0K -$788.0K -$1.300M
YoY Change -1464.21% -589.99% -5009.37%
% of Operating Profit -7.23%
Other Income/Expense, Net $11.68M $39.04M -$39.71M
YoY Change -194.06% 231.85%
Pretax Income -$4.020M $49.94M -$146.0M
YoY Change 14.64% -207.83% 1101.97%
Income Tax $20.00K $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$4.040M $49.94M -$64.48M
YoY Change 16.3% -207.8% -52.46%
Net Earnings / Revenue -83.2% 470.14% -1100.85%
Basic Earnings Per Share $0.47
Diluted Earnings Per Share -$32.58K $0.40 -$1.891M
COMMON SHARES
Basic Shares Outstanding 123.5M 106.4M
Diluted Shares Outstanding 123.6M

Balance Sheet

Concept 2021 Q4 2021 Q3 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $37.24M $72.72M $210.00
YoY Change 11733.49% 15899.12% -99.97%
Cash & Equivalents $37.24M $72.72M
Short-Term Investments
Other Short-Term Assets $2.000K $1.000K $51.31K
YoY Change -99.77% -98.48% -47.78%
Inventory $9.549M $5.747M
Prepaid Expenses $7.076M $9.133M
Receivables $5.233M $3.684M
Other Receivables $0.00 $0.00
Total Short-Term Assets $59.10M $91.28M $57.81K
YoY Change -18.1% 17439.53% -92.91%
LONG-TERM ASSETS
Property, Plant & Equipment $90.63M $91.01M
YoY Change 0.61%
Goodwill $123.3M $123.3M
YoY Change 0.0%
Intangibles $123.2M $123.7M
YoY Change -1.75%
Long-Term Investments $128.4M
YoY Change -55.98%
Other Assets $355.0K $354.0K
YoY Change -87.71%
Total Long-Term Assets $355.0M $357.0M $128.4M
YoY Change -1.06% 22.33% -55.98%
TOTAL ASSETS
Total Short-Term Assets $59.10M $91.28M $57.81K
Total Long-Term Assets $355.0M $357.0M $128.4M
Total Assets $414.1M $448.3M $128.4M
YoY Change -3.92% 53.33% -56.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.317M $7.031M $6.183M
YoY Change 72.86% 11695.0% 12692.76%
Accrued Expenses $11.66M $17.10M
YoY Change -13.31%
Deferred Revenue $2.196M $2.033M
YoY Change -54.52%
Short-Term Debt $0.00 $0.00 $1.109M
YoY Change
Long-Term Debt Due $3.051M $3.046M
YoY Change
Total Short-Term Liabilities $26.23M $29.21M $7.292M
YoY Change -1.69% 20572.28% 4678.2%
LONG-TERM LIABILITIES
Long-Term Debt $28.09M $28.02M $0.00
YoY Change
Other Long-Term Liabilities $335.0K $338.0K $40.16M
YoY Change -4.01% -96.87% 271.45%
Total Long-Term Liabilities $335.0K $338.0K $40.16M
YoY Change -4.01% -96.87% 271.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.23M $29.21M $7.292M
Total Long-Term Liabilities $335.0K $338.0K $40.16M
Total Liabilities $314.7M $352.1M $47.45M
YoY Change -23.67% 3112.99% 332.78%
SHAREHOLDERS EQUITY
Retained Earnings -$663.7M -$659.6M
YoY Change 17.77%
Common Stock $12.00K $10.00K $0.00
YoY Change 1100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares $0.00 $0.00
Shareholders Equity $99.42M $96.22M -$648.2M
YoY Change
Total Liabilities & Shareholders Equity $414.1M $448.3M $128.4M
YoY Change -3.92% 53.33% -56.08%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021 Q2
OPERATING ACTIVITIES
Net Income -$4.040M $49.94M -$64.48M
YoY Change 16.3% -207.8% -52.46%
Depreciation, Depletion And Amortization $2.606M $1.792M $1.087M
YoY Change 18.52%
Cash From Operating Activities -$32.05M -$77.22M -$382.9K
YoY Change 13125.34% 46786.5% -50.54%
INVESTING ACTIVITIES
Capital Expenditures -$2.303M -$3.900M
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $894.8K -$634.9K
YoY Change -100.0% -1017.76% -210.66%
Cash From Investing Activities -$2.303M -$3.005M -$634.9K
YoY Change -2346.83% 2982.24% -210.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.014M 98.47M 989.3K
YoY Change
NET CHANGE
Cash From Operating Activities -32.05M -77.22M -382.9K
Cash From Investing Activities -2.303M -3.005M -634.9K
Cash From Financing Activities -1.014M 98.47M 989.3K
Net Change In Cash -35.36M 18.24M -28.45K
YoY Change 25194.71% -7056.33% -85.8%
FREE CASH FLOW
Cash From Operating Activities -$32.05M -$77.22M -$382.9K
Capital Expenditures -$2.303M -$3.900M
Free Cash Flow -$29.74M -$73.32M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
true
celu License Arrangement Term
LicenseArrangementTerm
P5Y
celu License Arrangement Term
LicenseArrangementTerm
P5Y
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020 celu Valuation Input For Convertible Promissory Note Term
ValuationInputForConvertiblePromissoryNoteTerm
P7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y7M24D
CY2021Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
151000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
272000
CY2021Q3 celu Promissory Notes Receivable
PromissoryNotesReceivable
1909000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
14722000
CY2021Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
3879000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
354000
CY2021Q3 us-gaap Assets
Assets
448286000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7031000
CY2021Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
17102000
CY2021Q3 celu Financing Obligations Current
FinancingObligationsCurrent
3046000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26677000
CY2021Q3 celu Financing Obligations Noncurrent
FinancingObligationsNoncurrent
28022000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
celu Loss Recognized In Earnings From Change In Fair Values
LossRecognizedInEarningsFromChangeInFairValues
-2258000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72716000
dei Entity Central Index Key
EntityCentralIndexKey
0001752828
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38914
dei Entity Registrant Name
EntityRegistrantName
Celularity Inc.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1702591
dei Entity Address Address Line1
EntityAddressAddressLine1
170 Park Ave
dei Entity Address City Or Town
EntityAddressCityOrTown
Florham Park
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07932
dei City Area Code
CityAreaCode
(908)
dei Local Phone Number
LocalPhoneNumber
768-2170
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
123464113
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54311000
CY2021Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
1775000
CY2020Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
1134000
celu Reclassification Of Legacy Celularity Warrants To Equity
ReclassificationOfLegacyCelularityWarrantsToEquity
-96398000
CY2021Q3 celu Fair Value Net Assets Liability
FairValueNetAssetsLiability
37186000
CY2020Q4 celu Promissory Notes Receivable
PromissoryNotesReceivable
5416000
CY2021Q3 us-gaap Inventory Net
InventoryNet
5747000
CY2020Q4 us-gaap Inventory Net
InventoryNet
3850000
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9133000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6576000
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
873000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
91281000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
72160000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
91007000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
90077000
CY2021Q3 us-gaap Goodwill
Goodwill
123304000
CY2020Q4 us-gaap Goodwill
Goodwill
123304000
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
123739000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
125379000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
15202000
CY2020Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
1998000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2888000
CY2020Q4 us-gaap Assets
Assets
431008000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5390000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13451000
CY2020Q4 celu Financing Obligations Current
FinancingObligationsCurrent
3008000
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2033000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4828000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
29212000
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1783000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
7621000
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
255522000
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
273367000
CY2020Q4 celu Financing Obligations Noncurrent
FinancingObligationsNoncurrent
27634000
CY2021Q3 celu Warrant Liability
WarrantLiability
37186000
CY2020Q4 celu Warrant Liability
WarrantLiability
76640000
CY2021Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
7000
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
7000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
338000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
349000
CY2021Q3 us-gaap Liabilities
Liabilities
352070000
CY2020Q4 us-gaap Liabilities
Liabilities
412295000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3355000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
730000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
123464113
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
123464113
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
155640290
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18529453
CY2020Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
92000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
324000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
236000
CY2021Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
843000
CY2020Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
706000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18529453
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
10000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
0
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
90834
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
256000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
755847000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
32418000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-659641000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-563563000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2412000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1630000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
96216000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-531400000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
448286000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
431008000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10622000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16479000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11035000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23765000
CY2021Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
55000
CY2020Q3 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-4434000
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-4434000
CY2021Q3 celu Income Expense Related To Warrant Liabilities
IncomeExpenseRelatedToWarrantLiabilities
-39937000
CY2020Q3 celu Income Expense Related To Warrant Liabilities
IncomeExpenseRelatedToWarrantLiabilities
36960000
celu Income Expense Related To Warrant Liabilities
IncomeExpenseRelatedToWarrantLiabilities
-2258000
celu Income Expense Related To Warrant Liabilities
IncomeExpenseRelatedToWarrantLiabilities
52065000
CY2021Q3 celu Other Nonoperating Income Expenses
OtherNonoperatingIncomeExpenses
-109000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11217000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
63666000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38783000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21644000
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8327000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
58133000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
25363000
CY2021Q3 celu Change In Fair Value Of Contingent Consideration Liability
ChangeInFairValueOfContingentConsiderationLiability
-48549000
CY2020Q3 celu Change In Fair Value Of Contingent Consideration Liability
ChangeInFairValueOfContingentConsiderationLiability
-142599000
celu Change In Fair Value Of Contingent Consideration Liability
ChangeInFairValueOfContingentConsiderationLiability
-17845000
celu Change In Fair Value Of Contingent Consideration Liability
ChangeInFairValueOfContingentConsiderationLiability
-26136000
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
553000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
783000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1640000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2843000
CY2020Q3 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
129400000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
129400000
CY2021Q3 celu Operating Income Costs And Expenses
OperatingIncomeCostsAndExpenses
-276000
CY2020Q3 celu Operating Income Costs And Expenses
OperatingIncomeCostsAndExpenses
8161000
celu Operating Income Costs And Expenses
OperatingIncomeCostsAndExpenses
110587000
celu Operating Income Costs And Expenses
OperatingIncomeCostsAndExpenses
174015000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
10898000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4806000
us-gaap Operating Income Loss
OperatingIncomeLoss
-94108000
us-gaap Operating Income Loss
OperatingIncomeLoss
-162980000
CY2020Q3 celu Other Nonoperating Income Expenses
OtherNonoperatingIncomeExpenses
504000
celu Other Nonoperating Income Expenses
OtherNonoperatingIncomeExpenses
-2140000
celu Other Nonoperating Income Expenses
OtherNonoperatingIncomeExpenses
4099000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
39040000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-41504000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1970000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-53794000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
49938000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-46310000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-96078000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-216774000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4631000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
49938000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
828000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-30200000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-356777000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1444000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-46325000
us-gaap Net Income Loss
NetIncomeLoss
-96078000
us-gaap Net Income Loss
NetIncomeLoss
-212143000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.47
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.00
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-135618000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-490951000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
37000
CY2020Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
256000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1083000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.52
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106369910
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18416078
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-46325000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-536412000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-531400000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1009000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-81539000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-611930000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48071685
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18412761
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.40
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.52
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
123582822
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18416078
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48071685
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18412761
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-327420000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
28188000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-64477000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-648205000
CY2021Q3 celu Recapitalization Net Of Redemptions And Equity Issuance And Merger Costs Additional Paid In Capital
RecapitalizationNetOfRedemptionsAndEquityIssuanceAndMergerCostsAdditionalPaidInCapital
485596000
CY2021Q3 celu Reclassified From Warrant Liability To Additional Paid In Capital
ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital
96398000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
209000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
8880000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
49938000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
96216000
us-gaap Net Income Loss
NetIncomeLoss
-96078000
us-gaap Net Income Loss
NetIncomeLoss
-212143000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6211000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6341000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1356000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-8402000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
129400000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
113000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1005000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
38077000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
3355000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2258000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
52065000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-17845000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-26136000
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-4434000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-3206000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
41000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
754000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1465000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3778000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
745000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1522000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5336000
celu Sale Of Net Operating Losses And Research And Development Tax Credits
SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
1356000
celu Sale Of Net Operating Losses And Research And Development Tax Credits
SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
3765000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1364000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
237000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
3846000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-939000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-8633000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
5313000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-78051000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46362000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3900000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18462000
celu Proceeds From Promissory Note
ProceedsFromPromissoryNote
300000
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
15019000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3600000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3443000
celu Proceeds From Issuance Of Series B Redeemable Convertible Preferred Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts
102535000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
256000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
5000000
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
5000000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
223000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
52000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
83400000
celu Proceeds From Investment
ProceedsFromInvestment
20000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
9433000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
99576000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
102331000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
17925000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
52526000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69513000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43507000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87438000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
96033000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
11000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1601000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
5153000
celu Conversion Of Preferred Stock Into Common Stock
ConversionOfPreferredStockIntoCommonStock
550113000
celu Cancellation Of Treasury Stock
CancellationOfTreasuryStock
256000
celu Issuance Of Common Stock As Payment For Related Costs
IssuanceOfCommonStockAsPaymentForRelatedCosts
10795000
celu Reclassification Of Warrant Liabilities To Equity
ReclassificationOfWarrantLiabilitiesToEquity
96398000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
4524000
celu Change In Pipespac Related Costs Captured In Accounts Payable And Accrued Expenses
ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses
1103000
celu Commencement Of Capital Lease Obligations
CommencementOfCapitalLeaseObligations
-216000
celu Ultra Mist Systems Reclass From Inventory To Fixed Asset
UltraMISTSystemsReclassFromInventoryToFixedAsset
79000
celu Fair Value Of Warrants Issued In Connection With Serie B Preferred Stock Sale
FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale
17954000
celu Issuance Of Warrants At Estimated Fair Value
IssuanceOfWarrantsAtEstimatedFairValue
11988000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-08-24
celu Income Loss
IncomeLoss
-96078000
celu Income Loss
IncomeLoss
-212143000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106369910
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18416078
CY2021Q3 celu Business Combination Shares Exchange Ratio Description
BusinessCombinationSharesExchangeRatioDescription
1.00 share of Legacy Celularity for approximately 0.7686 shares of Celularity
CY2021Q3 celu Business Combination Shares Exchange Ratio
BusinessCombinationSharesExchangeRatio
0.7686
CY2021Q3 celu Number Of Clinical Trials
NumberOfClinicalTrials
4
celu Area Of Building
AreaOfBuilding
150000
us-gaap Net Income Loss
NetIncomeLoss
-96078000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-208233000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-659641000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, assumptions related to the Company’s goodwill and intangible impairment assessment, the valuation of inventory and of contingent consideration, accrual of research and development expenses, and the valuations of stock options and preferred stock warrants. The Company based its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</p>
celu Minimum Percentage Of Recognized Tax Benefit Likelihood Of Being Realized Upon Ultimate Settlement With Tax Authority
MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority
0.50
celu Gain On Change In Fair Value Of Warrants
GainOnChangeInFairValueOfWarrants
0
CY2021Q3 celu Income Loss
IncomeLoss
49938000
CY2020Q3 celu Income Loss
IncomeLoss
-46325000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48071685
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18412761
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
14107842
CY2021Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
3105070
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
123582822
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18416078
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48071685
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18412761
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.47
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.52
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.40
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.52
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
255522000
CY2021Q3 celu Warrant Liability Sponsor Warrants
WarrantLiabilitySponsorWarrants
20655000
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11467610
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
120482424
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
71184264
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
120482424
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q3 celu Number Of Business Segments
NumberOfBusinessSegments
3
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Significant Customers</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services. All trade accounts receivables are a result from product sales and services performed in the United States.<span style="font-size:12pt;"> </span>As of September 30, 2021 and December 31, 2020, one of the Company’s customers comprised approximately 38% and 24%, respectively, of the Company’s total outstanding accounts receivable. No single customer provided 10% or more of the revenue earned during the nine months ended September 30, 2021 and 2020.</p>
us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
At the Effective Time, by virtue of the First Merger and without any action on the part of GX, First Merger Sub, Legacy Celularity or the holders of any of the following securities:   a) each share of Legacy Celularity Common Stock (including shares of Legacy Celularity Common Stock resulting from the conversion of shares of Celularity Preferred Stock described above) that was issued and outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a number of shares of Company Class A common stock, par value $0.0001 per share (“Company Class A Common Stock”) equal to the Exchange Ratio (as defined below) (the “Per Share Merger Consideration”);   b) each share of Legacy Celularity Common Stock or Legacy Celularity Preferred Stock (together, “Legacy Celularity Capital Stock”) held in the treasury of Celularity was cancelled without any conversion thereof and no payment or distribution was made with respect thereto;   c) each share of First Merger Sub common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time was converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, par value $0.0001 per share, of the Surviving Corporation;   d) each Legacy Celularity Warrant (as to which no notice of exercise had been delivered to Legacy Celularity prior to the Closing) that was outstanding immediately prior to the Effective Time (and which would have otherwise been exercisable in accordance with its terms immediately following the Effective Time), became, to the extent consistent with the terms of such Legacy Celularity Warrant, the right to purchase shares of Company Class A Common Stock (and not Celularity Capital Stock) (each, a “Converted Warrant”) on the same terms and conditions (including exercisability terms) as were applicable to such Legacy Celularity Warrant immediately prior to the Effective Time, except that (A) each Converted Warrant became exercisable for that number of shares of Company Class A Common Stock equal to the product (rounded down to the nearest whole number) of (1) the number of shares of Legacy Celularity Common Stock that would have been issuable upon the exercise of a Legacy Celularity Warrant for cash and assuming the conversion of the Series B Preferred Stock underlying such outstanding Legacy Celularity Warrant into Legacy Celularity Common Stock (the “Celularity Warrant Shares”) subject to the Legacy Celularity Warrant immediately prior to the Effective Time and (2) the Exchange Ratio (as defined below); and (B) the per share exercise price for each share of Company Class A Common Stock issuable upon exercise of the Converted Warrant is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (1) the per share exercise price for each share of Series B Preferred Stock issuable upon exercise of such Celularity Warrant immediately prior to the Effective Time by (2) the Exchange Ratio (as defined below); and   e) each option to purchase Legacy Celularity Common Stock, whether or not exercisable and whether or not vested, that was outstanding immediately prior to the Effective Time (each, a “Legacy Celularity Option”) was assumed by GX and converted into an option to purchase shares of Company Class A Common Stock (each, a “Converted Option”).
CY2021Q3 celu Business Acquisition Transaction Costs Proceeds Net
BusinessAcquisitionTransactionCostsProceedsNet
108786000
CY2021Q3 us-gaap Business Acquisition Cost Of Acquired Entity Transaction Costs
BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
21658000
celu Subscription Agreements Description
SubscriptionAgreementsDescription
On the Closing Date, certain significant stockholders of Legacy Celularity or their affiliates (including Sorrento Therapeutics, Inc., Starr International Investments Ltd. and Dragasac Limited, an indirect wholly owned subsidiary of Genting Berhad, collectively, the “Subscribers”) purchased from Celularity an aggregate of 8,340,000 shares of Class A common stock (the “PIPE Shares”), for a purchase price of $10.00 per share and an aggregate purchase price of $83,400, pursuant to separate subscription agreements dated January 8, 2021 (collectively, the “Subscription Agreements”). Pursuant to the Subscription Agreements, the Company agreed to provide the Subscribers with certain registration rights with respect to the PIPE Shares.
celu Consideration Description
ConsiderationDescription
(i) calculate the goodwill attributed to the UltraMIST business, (ii) determine the allocation of arrangement consideration to the three performance obligations and (iii) determine the loss on sale of the UltraMIST business. The Company utilized a discounted cash flow model to value the UltraMIST business, which determined the fair value of the UltraMIST business was $15,019. Significant inputs of this discounted cash flow model included (i) a discount rate of 11%, (ii) tax rate of 26% and (iii) a long-term growth rate of 2%. The remaining proceeds of $9,505 were allocated to the license agreement on a residual basis. During the third quarter of 2020, Legacy Celularity recognized a loss on sale of UltraMIST of $4,434, which included approximately $40 in related professional fees. Due to Legacy Celularity’s tax position at the closing date, there was no tax impact resulting from the sale of the UltraMIST business.
CY2021Q3 celu Convertible Note Receivable
ConvertibleNoteReceivable
1909000
CY2021Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
73309000
CY2021Q3 celu Fair Value Net Assets Liability
FairValueNetAssetsLiability
37186000
CY2020Q4 celu Fair Value Net Assets Liability
FairValueNetAssetsLiability
76640000
CY2020 celu Stock And Warrant Issued During Period Value Preferred Stock And Warrants
StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants
17954000
CY2020 celu Proceeds From Issuance Of Warrant
ProceedsFromIssuanceOfWarrant
11988000
CY2020 celu Loss Recognized In Earnings From Change In Fair Values
LossRecognizedInEarningsFromChangeInFairValues
46698000
CY2020Q4 celu Fair Value Net Assets Liability
FairValueNetAssetsLiability
76640000
CY2020Q4 celu Fair Value Net Assets Liability
FairValueNetAssetsLiability
76640000
celu Asset Purchase Agreement Description
AssetPurchaseAgreementDescription
Legacy Celularity executed (i) an asset purchase agreement to sell certain assets comprising its MIST®/UltraMIST® business to Sanuwave and (ii) a five-year licensing agreement with Sanuwave for total consideration of $24,524 (the “Sanuwave Transaction”), of which $20,000 was paid at or prior to closing. The remaining $4,524 of the purchase price was financed through a convertible promissory note due on or before August 6, 2021. The convertible promissory note could have been converted into shares of Sanuwave stock at the election of the Company any time on or after January 1, 2021.
CY2020Q3 us-gaap Disposal Group Including Discontinued Operation Inventory1
DisposalGroupIncludingDiscontinuedOperationInventory1
1901000
CY2020Q3 us-gaap Disposal Group Including Discontinued Operation Intangible Assets
DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
13296000
CY2020Q3 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
452000
CY2020Q3 us-gaap Disposal Group Including Discontinued Operation Goodwill1
DisposalGroupIncludingDiscontinuedOperationGoodwill1
3764000
CY2020Q3 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
19413000
CY2021Q3 celu Warrant Liability Public Warrants
WarrantLiabilityPublicWarrants
16531000
CY2021Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
292708000
CY2020Q4 celu Convertible Note Receivable
ConvertibleNoteReceivable
4715000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
49715000
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
273367000
CY2020Q4 celu Preferred Stock Warrants
PreferredStockWarrants
76640000
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
350007000
CY2021Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2020Q4 celu Contingent Consideration Obligation
ContingentConsiderationObligation
273367000
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-17845000
CY2021Q3 celu Contingent Consideration Obligation
ContingentConsiderationObligation
255522000
CY2019Q4 celu Contingent Consideration Obligation
ContingentConsiderationObligation
328933000
CY2020 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-55566000
CY2020Q4 celu Contingent Consideration Obligation
ContingentConsiderationObligation
273367000
CY2021Q3 us-gaap Inventory Net
InventoryNet
5747000
CY2020Q4 us-gaap Inventory Net
InventoryNet
3850000
CY2021Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
3879000
CY2021Q3 celu Inventory Gross Current And Noncurrent
InventoryGrossCurrentAndNoncurrent
9650000
CY2020Q4 celu Inventory Gross Current And Noncurrent
InventoryGrossCurrentAndNoncurrent
5852000
CY2021Q3 celu Inventory Reserve Current And Noncurrent
InventoryReserveCurrentAndNoncurrent
24000
CY2020Q4 celu Inventory Reserve Current And Noncurrent
InventoryReserveCurrentAndNoncurrent
4000
CY2021Q3 celu Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
9626000
CY2020Q4 celu Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
5848000
CY2020Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
1998000
CY2021Q3 celu Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
9626000
CY2020Q4 celu Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
5848000
CY2021Q3 celu Face Value Of Notes Receivable
FaceValueOfNotesReceivable
4000000
CY2020Q4 celu Face Value Of Notes Receivable
FaceValueOfNotesReceivable
4000000
CY2020 celu Percentage Of Coupon Rate
PercentageOfCouponRate
0.12
CY2021Q3 celu Valuation Model That Relate To Sanuwave Common Stock
ValuationModelThatRelateToSanuwaveCommonStock
0.12
CY2020Q4 celu Valuation Model That Relate To Sanuwave Common Stock
ValuationModelThatRelateToSanuwaveCommonStock
0.19
CY2021Q3 celu Inventory Raw Materials Current And Noncurrent
InventoryRawMaterialsCurrentAndNoncurrent
913000
CY2020Q4 celu Inventory Raw Materials Current And Noncurrent
InventoryRawMaterialsCurrentAndNoncurrent
376000
CY2021Q3 celu Inventory Work In Progress Current And Noncurrent
InventoryWorkInProgressCurrentAndNoncurrent
2431000
CY2020Q4 celu Inventory Work In Progress Current And Noncurrent
InventoryWorkInProgressCurrentAndNoncurrent
460000
CY2021Q3 celu Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
6306000
CY2020Q4 celu Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
5016000
CY2021Q3 celu Prepaid Clinical Expense
PrepaidClinicalExpense
3459000
CY2020Q4 celu Prepaid Clinical Expense
PrepaidClinicalExpense
5151000
CY2021Q3 celu Prepaid Software Related Expenses
PrepaidSoftwareRelatedExpenses
4294000
CY2020Q4 celu Prepaid Software Related Expenses
PrepaidSoftwareRelatedExpenses
479000
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
443000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
206000
CY2021Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
937000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
740000
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9133000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6576000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
103732000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
97163000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12725000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7086000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
91007000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
90077000
CY2021Q3 us-gaap Sale Leaseback Transaction Accumulated Depreciation
SaleLeasebackTransactionAccumulatedDepreciation
5512000
CY2020Q4 us-gaap Sale Leaseback Transaction Accumulated Depreciation
SaleLeasebackTransactionAccumulatedDepreciation
2624000
CY2021Q3 us-gaap Depreciation
Depreciation
1792000
CY2020Q3 us-gaap Depreciation
Depreciation
1512000
us-gaap Depreciation
Depreciation
4571000
us-gaap Depreciation
Depreciation
3498000
CY2021Q3 us-gaap Goodwill
Goodwill
123304000
CY2020Q4 us-gaap Goodwill
Goodwill
123304000
CY2021Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
23993000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
23993000
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8754000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
7114000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
15239000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
16879000
CY2021Q3 celu Acquired Product Rights
AcquiredProductRights
108500000
CY2020Q4 celu Acquired Product Rights
AcquiredProductRights
108500000
CY2020 celu Indefinite Lived Intangible Assets Amortization Method
IndefiniteLivedIntangibleAssetsAmortizationMethod
indefinite
celu Indefinite Lived Intangible Assets Amortization Method
IndefiniteLivedIntangibleAssetsAmortizationMethod
indefinite
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
123739000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
125379000
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
553000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
783000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1640000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2843000
CY2020Q3 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
129400000
CY2021Q3 celu Accrued Clinical Trial Expense
AccruedClinicalTrialExpense
1310000
CY2020Q4 celu Accrued Clinical Trial Expense
AccruedClinicalTrialExpense
2644000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3368000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2866000
CY2021Q3 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
5266000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4106000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4991000
CY2021Q3 celu Accruals For Construction In Progress
AccrualsForConstructionInProgress
70000
CY2020Q4 celu Accruals For Construction In Progress
AccrualsForConstructionInProgress
171000
CY2021Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
4000
CY2020Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
292000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2978000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2487000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17102000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13451000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
602000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1277000
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
42686195
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
729000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2861000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2895000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2969000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
3042000
CY2021Q3 celu Operating Leases Future Minimum Payments Due After Four Years
OperatingLeasesFutureMinimumPaymentsDueAfterFourYears
76647000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
89143000
us-gaap Common Stock Voting Rights
CommonStockVotingRights
common stock are entitled to one vote per share
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
Preferred Stock were entitled to vote
us-gaap Preferred Stock Dividend Payment Terms
PreferredStockDividendPaymentTerms
The holders of Preferred Stock were entitled to receive noncumulative dividends when, as and if declared by the board of directors. Dividends accrued on the Preferred Stock at a rate of 6% of the Original Issue Price per year; however, such dividends were only payable when, as and if declared by the board of directors. Holders of the Preferred Stock were to be paid dividends prior and in preference to any dividends on common stock. As of the Closing Date, no cash dividends were declared or paid.
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.06
us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.008
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.804
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.13
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
269007
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue
3.83
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
2613217
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue
10.21
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13723000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3170000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
15734000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y4M24D
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8880000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1083000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
38077000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3355000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10622000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3355000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16479000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11035000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
12449000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3833000
celu Contract With Customer Liability Increase Decrease For Contract From Business Combination And Deferred Revenue
ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue
3528000
celu Contract With Customer Liability Increase Decrease For Contract From Business Combination And Deferred Revenue
ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue
13734000
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
12161000
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
3898000
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3816000
CY2020Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
13669000
celu Incentive Payment
IncentivePayment
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.021
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4631000
celu Net Operating Losses And Unused Research And Development Tax Credits Sold
NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold
1458000
celu Net Operating Losses And Unused Research And Development Tax Credits Sold
NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold
4005000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
11000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4000
CY2020Q2 celu Reimbursement Of Cost Under License Agreement
ReimbursementOfCostUnderLicenseAgreement
75000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
896000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
835000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q3 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3
CY2021Q3 us-gaap Assets
Assets
448286000
CY2020Q4 us-gaap Assets
Assets
431008000
CY2021Q3 celu Net Sales
NetSales
10622000
CY2021Q3 us-gaap Gross Profit
GrossProfit
8311000
CY2021Q3 us-gaap Direct Operating Costs
DirectOperatingCosts
45409000
CY2021Q3 celu Segment Contribution
SegmentContribution
-37098000
CY2021Q3 celu Indirect Expenses
IndirectExpenses
-47996000
CY2021Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
10898000
CY2020Q3 celu Net Sales
NetSales
3355000
CY2020Q3 us-gaap Gross Profit
GrossProfit
2322000
CY2020Q3 us-gaap Direct Operating Costs
DirectOperatingCosts
19544000
CY2020Q3 celu Segment Contribution
SegmentContribution
-17222000
CY2020Q3 celu Indirect Expenses
IndirectExpenses
-12416000
CY2020Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-4806000
celu Net Sales
NetSales
16479000
us-gaap Gross Profit
GrossProfit
11486000
us-gaap Direct Operating Costs
DirectOperatingCosts
121799000
celu Segment Contribution
SegmentContribution
-110313000
celu Indirect Expenses
IndirectExpenses
-16205000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-94108000
celu Net Sales
NetSales
11035000
us-gaap Gross Profit
GrossProfit
7273000
us-gaap Direct Operating Costs
DirectOperatingCosts
64146000
celu Segment Contribution
SegmentContribution
-56873000
celu Indirect Expenses
IndirectExpenses
106107000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-162980000

Files In Submission

Name View Source Status
0001564590-21-056724-index-headers.html Edgar Link pending
0001564590-21-056724-index.html Edgar Link pending
0001564590-21-056724.txt Edgar Link pending
0001564590-21-056724-xbrl.zip Edgar Link pending
celu-10q_20210930.htm Edgar Link pending
celu-10q_20210930_htm.xml Edgar Link completed
celu-20210930.xsd Edgar Link pending
celu-20210930_cal.xml Edgar Link unprocessable
celu-20210930_def.xml Edgar Link unprocessable
celu-20210930_lab.xml Edgar Link unprocessable
celu-20210930_pre.xml Edgar Link unprocessable
celu-ex1025_196.htm Edgar Link pending
celu-ex311_6.htm Edgar Link pending
celu-ex312_9.htm Edgar Link pending
celu-ex321_8.htm Edgar Link pending
celu-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending